Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sorafenib Combined With Cisplatin and Gemcitabine for the Treatment of Patients With Advanced Renal Collecting Duct Carcinoma: A Pilot, Open Study

Trial Profile

Sorafenib Combined With Cisplatin and Gemcitabine for the Treatment of Patients With Advanced Renal Collecting Duct Carcinoma: A Pilot, Open Study

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2018

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin; Gemcitabine
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Nov 2018 Status changed from active, no longer recruiting to completed.
    • 19 Jun 2018 Primary endpoint (Progress-free survival (PFS)) has been met, according to results published in the European Journal of Cancer.
    • 19 Jun 2018 Results (n=26) published in the European Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top